FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) announced that the slate of board of directors nominees brought forward by a group of concerned shareholders received the necessary votes at the company’s annual general and special meeting on May 14.
The nominees of the concerned group, led by Anthony Durkacz and Zeeshan Saeed, were each elected, along with Frank Lavelle and Donal Carroll, to hold office for the ensuing year. However, following his election, Lavelle resigned, the company said. Nitin Kaushal and Larry Latowsky are the board’s remaining two directors.
“We are pleased to see that FSD shareholders have shown their overwhelming support for the concerned shareholders and the concerned shareholders’ nominees,” Durkacz and Saeed said in a statement. “We look forward to restoring FSD and know there is a lot of work ahead of us. We would like to thank all shareholders for their patience and support.”
READ: FSD Pharma files New Animal Drug Application with FDA for FSD201 to treat gastrointestinal enteropathy in dogs
At a meeting of the board following the shareholder meeting, Durkacz and Saeed were appointed executive co-chairmen of the board.
Additionally, shareholders approved a special resolution to change the registered office of the company from Durham Region, Ontario to a location in Toronto.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel